Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Aging Clin Exp Res ; 28(2): 189-95, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26240032

ABSTRACT

BACKGROUND: An increase in daily doses of protein and fiber for the elderly is relevant in preventing sarcopenia and preserving intestinal balance. However, such intake of supplements is often compromised by the lack of adherence among the elderly. OBJECTIVES: The main objective was to evaluate the perception of the hedonic qualities of compote enriched with NUTRALYS(®) pea protein, NUTRALYS(®)W hydrolyzed wheat gluten and NUTRIOSE(®) soluble fiber and the changes in that perception due to repeated consumption. The secondary objectives were to evaluate the evolution in the quantity of compote eaten, satisfaction with consumption and any changes in fatigue, digestive comfort and digestive tolerance when eating compote every other day for 3 weeks. METHOD: An observational study was conducted in nursing homes on volunteers aged 70-90 years. The compote was proposed as a lunchtime dessert every two days for a period of three consecutive weeks. All criteria were evaluated at days D0 and/or D1, D7, D15 and D21, except for the amount of compote eaten, evaluated after each meal at which it was served. RESULTS: When first tasted, the compote was judged 'rather pleasant' to 'very pleasant' by 91.6 % and this rating held up at 79.2 % (p = 0.1797) after 1 week, 83.3 % (p = 0.3173) after 2 weeks and 79.2 % (p = 0.2568) after 3 weeks. Average consumption of compote was stable and varied between a maximum of 79.5 % of the total quantity at inclusion to a minimum of 61.5 % recorded on D17. The other parameters did not change significantly. CONCLUSION: Pea protein, hydrolyzed wheat gluten and soluble fiber seem to provide an appropriate form of protein and fiber supplementation in the diets of elderly people in nursing homes.


Subject(s)
Dextrins/administration & dosage , Dietary Fiber/administration & dosage , Eating/psychology , Homes for the Aged/statistics & numerical data , Nursing Homes/statistics & numerical data , Patient Compliance/statistics & numerical data , Sarcopenia , Aged , Aged, 80 and over , Dietary Supplements , Female , France , Humans , Male , Malus , Plant Proteins, Dietary/administration & dosage , Portion Size , Sarcopenia/diet therapy , Sarcopenia/prevention & control , Treatment Outcome
2.
J Anim Sci ; 93(5): 2191-200, 2015 May.
Article in English | MEDLINE | ID: mdl-26020315

ABSTRACT

Dietary fermentable fiber is known to benefit intestinal health of companion animals. Soluble corn fiber (SCF) was evaluated for its chemical composition, nitrogen-corrected true ME (TMEn) content, in vitro digestion and fermentation characteristics, and in vivo effects on nutrient digestibility, fecal fermentation end products, and modulation of the fecal microbiome of dogs. Soluble corn fiber contained 78% total dietary fiber, all present as soluble dietary fiber; 56% was low molecular weight soluble fiber (did not precipitate in 95% ethanol). The SCF also contained 26% starch and 8% resistant starch and had a TMEn value of 2.6 kcal/g. Soluble corn fiber was first subjected to in vitro hydrolytic-enzymatic digestion to determine extent of digestibility and then fermented using dog fecal inoculum, with fermentative outcomes measured at 0, 3, 6, 9, and 12 h. Hydrolytic-enzymatic digestion of SCF was only 7%. In vitro fermentation showed increased (P < 0.05) concentrations of short-chain fatty acids through 12 h, with acetate, propionate, and butyrate reaching peak concentrations of 1,803, 926, and 112 µmol/g DM, respectively. Fermentability of SCF was higher (P < 0.05) than for cellulose but lower (P < 0.05) than for pectin. In the in vivo experiment, 10 female dogs (6.4 ± 0.2 yr and 22 ± 2.1 kg) received 5 diets with graded concentrations of SCF (0, 0.5, 0.75, 1.0, or 1.25% [as-is basis]) replacing cellulose in a replicated 5 × 5 Latin square design. Dogs were first acclimated to the experimental diets for 10 d followed by 4 d of total fecal collection. Fresh fecal samples were collected to measure fecal pH and fermentation end products and permit a microbiome analysis. For microbiome analysis, extraction of DNA was followed by amplification of the V4 to V6 variable region of the 16S rRNA gene using barcoded primers. Sequences were classified into taxonomic levels using a nucleotide basic local alignment search tool (BLASTn) against a curated GreenGenes database. Few changes in nutrient digestibility or fecal fermentation end products or stool consistency were observed, and no appreciable modulation of the fecal microbiome occurred. In conclusion, SCF was fermentable in vitro, but higher dietary concentrations may be necessary to elicit potential in vivo responses.


Subject(s)
Animal Nutritional Physiological Phenomena , Dietary Fiber/analysis , Digestion/physiology , Energy Metabolism/physiology , Zea mays/chemistry , Animal Feed/analysis , Animals , Bacteria/genetics , Base Sequence , Cellulose/analysis , Chickens , Computational Biology , Diet/veterinary , Dogs , Fatty Acids, Volatile/analysis , Feces/chemistry , Feces/microbiology , Female , Fermentation , Molecular Sequence Data , Pectins/analysis , RNA, Ribosomal, 16S/genetics , Sequence Alignment , Sequence Analysis, DNA
3.
J Control Release ; 197: 121-30, 2015 Jan 10.
Article in English | MEDLINE | ID: mdl-25445696

ABSTRACT

The first proof of concept in vivo for a new type of microbiota-sensitive film coatings allowing for colon targeting is presented. The efficacy of these polysaccharide barriers to optimize drug release for the treatment of inflammation is demonstrated in an experimental colitis model with Wister rats. 5-Aminosalicylic acid (5-ASA) pellets were prepared by extrusion-spheronization and coated with Nutriose:ethylcellulose (EC) 1:4 or peas starch:ethylcellulose 1:2 blends. The pellets were mixed with standard chow, and the daily drug dose was 150mg/kg. For reasons of comparison, also commercially available Pentasa pellets and placebo pellets were studied. At day 3 after the beginning of the treatment, colitis was induced by intrarectal administration of trinitrobenzene sulfonic acid (TNBS). Animals were sacrificed on day 6. Macroscopic and histological evaluations of colitis were performed blindly. In addition, inflammatory markers were evaluated using ELISA and real-time PCR. Rats receiving TNBS and placebo pellets developed a severe colitis in the distal half of the colon. 5-ASA administered in the form of Pentasa pellets reduced macroscopic inflammation by only 5%. In contrast, the colon lesions were much less severe upon treatment with Nutriose:EC- and peas starch:EC-coated pellets: The macroscopic score was reduced by 25 and 24%, respectively. Decreases of 37 and 38% of the histological lesions confirmed the efficacy of these new colon targeting systems. Also, inflammatory markers (MPO, IL-1ß mRNA, TNF mRNA) were significantly decreased in rats receiving Nutriose:EC- and peas starch:EC-coated pellets compared to Pentasa pellets. Furthermore, real-time PCR analysis indicated increased activation of the target receptor PPAR-γ and the HMGCS2 gene in rats upon administration of 5-ASA loaded Nutriose:EC- and peas starch:EC pellets compared to the commercial product. Also, HPLC-MS/MS analysis of plasma samples demonstrated that the level of the main metabolite of the drug (N-acetyl-5-ASA) was much lower upon administration of Nutriose:EC or peas starch:EC coated pellets compared to Pentasa pellets, indicating that undesired premature drug release in the upper gastrointestinal tract was more effectively hindered. In addition to the rat study, in vivo imaging of transgenic mice expressing the luciferase gene evidenced much more pronounced PPAR-γ activation upon 5-ASA administration in the form of Nutriose:EC-coated pellets versus Pentasa pellets. All these results clearly demonstrate the superiority of these microbiota-sensitive polysaccharide-based film coatings for colon targeting in vivo.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Colitis/drug therapy , Colon/metabolism , Drug Delivery Systems , Mesalamine/administration & dosage , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cellulose/analogs & derivatives , Cellulose/chemistry , Colitis/chemically induced , Colitis/metabolism , Dextrins/chemistry , Hydroxymethylglutaryl-CoA Synthase/genetics , Interleukin-1beta/genetics , Male , Mesalamine/pharmacokinetics , Mesalamine/pharmacology , Mesalamine/therapeutic use , Mice, Transgenic , Microbiota , PPAR gamma/genetics , PPAR gamma/metabolism , Peroxidase/metabolism , RNA, Messenger/metabolism , Rats, Wistar , Starch/chemistry , Trinitrobenzenesulfonic Acid , Tumor Necrosis Factor-alpha/genetics
4.
Eur J Paediatr Dent ; 14(4): 303-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24313583

ABSTRACT

AIM: The effects on plaque parameters of sugar free chewing-gums (CG) sweetened with either maltitol or xylitol were assessed to better understand the role polyols can play in dental caries prevention. MATERIALS AND METHODS: A double-blind, parallel, randomised, controlled study was conducted in China. Subjects (N = 258, age = 13 to 15 years-old) were divided into 4 groups: 2 receiving polyols CG, containing respectively maltitol or xylitol, a group receiving gum base (placebo) and a negative control group not receiving any gum. CG were chewed for 30 days. This corresponds to a 10 g consumption of polyol per day. Plaque parameters (growth, pH, bacteria and insoluble glucans) were evaluated throughout the experimental period. RESULTS: All parameters studied were significantly modified with gum base compared to no-gum: plaque pH increased; plaque growth, bacteria (S. mutans, S. sobrinus, A. viscosus and Lactobacillus) and insoluble glucans decreased. Maltitol and xylitol CG led similarly to a higher plaque pH (AUC, p⋜0.05) on short (at baseline after the first CG consumption) and long term (after 4 weeks of daily CG consumption), with or without saliva stimulation compared to both control and placebo groups. They led to a decrease in plaque growth (p=0.02) over the experimental period compared to controls. Moreover, they significantly reduced the concentration of 4 cariogenic bacteria species (p⋜0.05) in dental plaque compared to gum base. CONCLUSION: Sugar free CG sweetened with either maltitol or xylitol can similarly reduce plaque acidogenicity compared to gum base through a decrease in oral bacteria presence. The use of a gum base placebo allowed to isolate effects on parameters involved in dental caries development specific to maltitol and xylitol, and to show these effects were similar.


Subject(s)
Cariostatic Agents/therapeutic use , Chewing Gum , Dental Caries/prevention & control , Maltose/analogs & derivatives , Sugar Alcohols/therapeutic use , Xylitol/therapeutic use , Actinomyces viscosus/isolation & purification , Adolescent , Analysis of Variance , Area Under Curve , Dental Plaque/chemistry , Dental Plaque/microbiology , Dental Plaque Index , Double-Blind Method , Glucans/analysis , Humans , Hydrogen-Ion Concentration , Lactobacillus/isolation & purification , Maltose/therapeutic use , Statistics, Nonparametric , Streptococcus mutans/isolation & purification , Streptococcus sobrinus/isolation & purification
5.
J Anim Sci ; 91(11): 5344-52, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24045465

ABSTRACT

Potato fiber (PF), a coproduct of potato starch manufacture, was evaluated as a potential novel fiber source in dog food. Potato fiber contained 55% total dietary fiber, 29% starch, 4% crude protein, and 2% acid-hydrolyzed fat. The PF substrate was evaluated for chemical composition, in vitro digestion and fermentation characteristics, and in vivo responses. For the in vitro hydrolytic-enzymatic digestion and fermentation experiment, raw and cooked PF substrates were first subjected to hydrolytic-enzymatic digestion to determine OM disappearance and then fermented using dog fecal inoculum. Fermentation characteristics were then measured at 0, 3, 6, 9, and 12 h. For the in vivo experiment, 10 female mixed-breed dogs (6.13±0.17 yr; 22±2.1 kg) were provided 5 diets with graded concentrations (0%, 1.5%, 3%, 4.5%, or 6%) of PF in a replicated 5×5 Latin square design. Dogs were acclimated to the test diet for 10 d, followed by 4 d of total fecal collection. Fresh fecal samples were collected to measure fecal pH and fermentation end products. In vitro digestion revealed that raw and cooked PF were 32.3% and 27.9% digested enzymatically, whereas in vitro fermentation showed that PF was fermentable through 9 h. Raw PF had greater (P<0.05) acetate, propionate, and total short-chain fatty acid (SCFA) concentrations at the 12-h time point compared with cooked PF. The in vivo experiment showed no differences in apparent total tract DM, OM, CP, acid-hydrolyzed fat, or energy digestibility of diets containing graded concentrations of PF. However, total dietary fiber digestibility exhibited a linear increase (P<0.01) with increasing PF concentrations in the diet. Overall, linear increases (P<0.01) were observed for all individual and total SCFA, with a concomitant linear decrease (P<0.01) in fecal pH with increasing dietary PF. Fecal protein catabolite concentrations were low or undetectable, with the exception of spermidine, which exhibited a linear increase with increasing concentrations of PF. These findings indicated that inclusion of PF elicited favorable fermentation characteristics without negatively affecting nutrient digestibility or stool characteristics, indicating that PF could be a functional dietary fiber source in dog foods.


Subject(s)
Animal Feed/analysis , Diet/veterinary , Dietary Fiber/analysis , Dogs/physiology , Solanum tuberosum/chemistry , Animal Nutritional Physiological Phenomena , Animals , Digestion/physiology , Feces/chemistry , Female , Fermentation
6.
J Int Med Res ; 40(1): 211-24, 2012.
Article in English | MEDLINE | ID: mdl-22429361

ABSTRACT

OBJECTIVES: The prebiotic potential of NUTRIOSE®--a sugar-free, digestion-resistant dextrin--was evaluated in two randomized, placebo-controlled trials that included 48 and 40 healthy volunteers, respectively. METHODS: In study 1, the effect on colonic bacteria of NUTRIOSE® 10, 15 or 20 g/day administered for 14 days was examined; in study 2, gut microbial changes in response to NUTRIOSE® 8 g/day for 14 days were monitored using real-time polymerase chain reaction analysis. RESULTS: NUTRIOSE® increased proliferation of Bacteroides and inhibited Clostridum perfringens in both studies, increased ß-glucosidase activity (at 10 and 15 g/day) and decreased colonic pH (at 20 g/day). The increase in short-chain fatty acid production with NUTRIOSE® consumption was not statistically significant. There were no indications of gastrointestinal intolerance at any dose. CONCLUSIONS: According to commonly accepted definitions, NUTRIOSE® is a prebiotic soluble fibre that provides a beneficial effect on colonic ecology while preserving digestive comfort.


Subject(s)
Dextrins/pharmacology , Dietary Fiber , Health , Intestines/drug effects , Intestines/microbiology , Prebiotics , Administration, Oral , Adult , Bacteroides/drug effects , Bacteroides/growth & development , Clostridium perfringens/drug effects , Colony Count, Microbial , Dextrins/administration & dosage , Feces/microbiology , Female , Humans , Hydrogen-Ion Concentration/drug effects , Male , Middle Aged , Solubility/drug effects
7.
Drug Dev Ind Pharm ; 37(10): 1150-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21417601

ABSTRACT

BACKGROUND: Colon specific drug delivery can significantly improve the efficacy of local treatments of inflammatory bowel diseases. Film coatings containing the starch derivative Nutriose have recently been reported to minimize 5-ASA release in media simulating the upper gastro intestinal tract (GIT), while releasing the drug in a time-controlled manner upon contact with feces from Crohn's Disease and Ulcerative Colitis patients. It was the aim of this study to prepare Nutriose-containing matrix pellets and mini tablets in order to avoid a film coating step. METHODS: Highly dosed matrix pellets were prepared by extrusion-spheronization, highly dosed mini tablets by compression. Various types of lipids were added and drug release measured in 0.1 N HCl and phosphate buffer pH 6.8, optionally containing pepsin and pancreatin. RESULTS: The type of added lipid and the preparation technique, in particular the curing conditions, significantly affected the resulting drug release kinetics. Glyceryl palmitostearate containing pellets and mini tablets showed the most promising results upon appropriate curing, minimizing premature drug release in media simulating the upper GIT. CONCLUSION: The proposed novel multiparticulates do not require a film coating step and show an interesting potential for site-specific drug delivery to the colon of inflammatory bowel disease patients.


Subject(s)
Colon/metabolism , Delayed-Action Preparations/administration & dosage , Drug Delivery Systems/methods , Excipients/administration & dosage , Inflammatory Bowel Diseases/drug therapy , Tablets/administration & dosage , Delayed-Action Preparations/chemistry , Drug Compounding/methods , Excipients/chemistry , Humans , Particle Size , Polysaccharides/administration & dosage , Polysaccharides/chemistry , Tablets/chemistry
8.
Food Chem Toxicol ; 46(10): 3254-61, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18701086

ABSTRACT

Nutriose is a glucose polysaccharide produced by the chromatographic separation of a dextrin fraction derived from maize, wheat or other edible starches. Animal safety studies conducted on Nutriose FB are reported. They include an acute oral and a 90-day study in rats and short-term in bacteria (Ames test) and a mutation assay at the TK locus in L5178Y mouse lymphoma cells. An acute oral study in Sprague-Dawley rats established the LD(50) as greater than 2000 mg/kg. In a 90-day, oral subchronic study, Sprague-Dawley rats were administered Nutriose FB in their diet at doses of 0, 1.25%, 2.5% or 5% for 13 weeks. Neither mortality nor significant behavioral changes occurred during the study. The consumption of Nutriose FB did not have any effect on body weight or on feed or water consumption. Blood coagulation and hematology and blood and urine biochemistry did not reveal any toxic effect of the compound. No treatment-related histopathological differences were observed between control and test groups. Adverse clinical observations, including ophthalmological observations, were marginal and not considered treatment-related. There was no effect of Nutriose FB on relative or absolute organ weight of rats of either sex, except for the increase in caecum content and caecum mucosa. The increase in caecum weight is considered a physiological adaptation seen after the ingestion of indigestible carbohydrates and is not considered a toxicological effect. The No-Observed-Adverse-Effect-Levels (NOAELs) were established by the highest tested doses: 4.4 g/kg bw/day in males and 6.5 g/kg bw/day in females. Mutation assays in bacteria (Ames tests) and in mammalian cells (tk locus in mouse lymphoma cells) were negative with Nutriose FB.


Subject(s)
Dextrins/administration & dosage , Dextrins/adverse effects , Animals , Body Weight/drug effects , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Lethal Dose 50 , Male , Mice , Mutagenicity Tests , Rats , Rats, Sprague-Dawley , Sex Characteristics
SELECTION OF CITATIONS
SEARCH DETAIL
...